Shares of Bio-Techne Corp. rallied 5.67% to $63.03 Monday, on what proved to be an all-around favorable trading session for ...

Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licensing deal, raising new ...

The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...

Bio-Techne (TECH) is back in focus after a recent analyst downgrade that cited softer organic growth and a weaker free cash ...

Instil Bio (NASDAQ:TIL) stock fell 15% Tuesday after the company announced that its wholly-owned subsidiary Axion Bio has decided to discontinue clinical developm ...

Key Insights Institutions' substantial holdings in Nuvation Bio implies that they have significant influence over ...

Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized ...

After diving over 17% on January 2, shares in biopharma company Intelligent Bio Solutions ($INBS) are back with a rally, ...

Investing.com -- FibroGen Inc (NASDAQ:FGEN) stock rose 5% on Wednesday after the company announced it would rebrand as Kyntra Bio, reflecting its sharpened focus on oncology and rare disease therapies ...

Panacea Bio share price has gained 7.27% in the past five sessions and nearly 21% in a month. However, the scrip has declined ...

NEW YORK CITY, NEW YORK / ACCESS Newswire / January 10, 2026 / New to The Street, the nationally syndicated business ...

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...